Stripe funds $500 million to beat the common cold

A $500 million bid to wipe out the common cold is underway, backed by Stripe and a constellation of AI leaders. Stripe is funding the nonprofit alongside Anthropic, OpenAI, and Bill Gates, with a stated aim to prevent both the common cold and the flu and, in the longer run, to get rid of respiratory viruses altogether. The plan sits at the intersection of engineering ambition and public health, a topic highlighted in MIT Technology Review’s Engineering issue as engineers take on problems that scale from nanoscale chipmaking to planetary challenges.

The team reports that modern technologies will be put to work to counter respiratory infections, drawing on the resources and perspectives of AI labs and philanthropic partners. The nonprofit’s stated goal is ambitious but clear: translate advances in AI and related fields into practical tools and strategies that reduce the burden of respiratory viruses. In the Engineering issue context, the venture represents a concrete example of how engineering mindsets can be mobilized toward health outcomes, not just code and prototypes.

For product leaders and AI engineers, the initiative signals a shift in how big bets are made about technology’s role in health. It is a collaboration that blends payments platform scale, deep learning expertise, and philanthropic capital to pursue a problem that touches billions of people each year. The project will be watched closely for how it handles governance, data access, and collaboration with health researchers, regulators, and practitioners who must translate AI insights into real world interventions.

From a practitioner standpoint, there are several concrete constraints and tradeoffs to watch:

In a field where the ceiling of what AI can achieve in health is still being defined, this multi-sponsor bet reflects a willingness to test engineering discipline against one of humanity’s oldest challenges. If the initiative can move from promising models to durable, scalable interventions while maintaining rigorous governance, it could set a precedent for how technology firms, researchers, and funders collaborate to make tangible public health progress.